Status:
COMPLETED
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Cutaneous T-cell Lymphoma
Sezary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher) who have progressive, persistent, or recurrent disease on or following 2 other therapies, one of which must ...
Eligibility Criteria
Inclusion
- Patients with Cutaneous T-cell Lymphoma (Stage 1B or higher)
- Age: over 18 years of age
- Have the ability to swallow capsules.
- You must be at least 3 weeks from any prior chemotherapy or anticancer therapy treatment and have recovered from any side effects of that treatment.
- Patients also require adequate heart, liver, and kidney function.
Exclusion
- Pregnant and nursing women and those with known allergy to the study drug are excluded from this study.
- Patients are excluded if they are currently receiving chemotherapy, radiation therapy, or other investigational anti-cancer therapy.
- Patients diagnosed with HIV, active hepatitis or who require intravenous antibiotics or antifungal agents are not permitted.
Key Trial Info
Start Date :
February 3 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 13 2006
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00091559
Start Date
February 3 2005
End Date
March 13 2006
Last Update
April 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.